Last10K.com

Rexahn Pharmaceuticals, Inc. (RNN) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

Rexahn Pharmaceuticals, Inc.

CIK: 1228627 Ticker: RNN
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2016
Feb. 24, 2017
Jun. 30, 2016
Document And Entity Information [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2016  
Entity Registrant NameREXAHN PHARMACEUTICALS, INC.  
Entity Central Index Key0001228627  
Current Fiscal Year End Date--12-31  
Entity Filer CategoryAccelerated Filer  
Document Fiscal Year Focus2016  
Document Fiscal Period FocusFY  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Well-known Seasoned IssuerNo  
Trading Symbolrnn  
Entity Public Float  $ 51,498,946
Entity Common Stock, Shares Outstanding 237,443,785 

View differences made from one year to another to evaluate Rexahn Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Rexahn Pharmaceuticals, Inc..

Continue

Assess how Rexahn Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Rexahn Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheet
Balance Sheet (parenthetical)
Statement Of Cash Flows
Statement Of Comprehensive Loss
Statement Of Operations
Statement Of Stockholders' Equity
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (details)
Accounts Payable And Accrued Expenses (tables)
Commitments And Contingencies
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (schedule Of Future Rental Payments) (details)
Commitments And Contingencies (tables)
Common Stock
Common Stock (narrative) (details)
Common Stock (schedule Of Stock Option And Stock Warrant Exercises) (details)
Common Stock (summary Of Allocation Of Proceeds From Offering) (details)
Common Stock (summary Of Issuances) (details)
Common Stock (tables)
Deferred Research And Development Arrangements
Deferred Research And Development Arrangements (details)
Equipment, Net
Equipment, Net (details)
Equipment, Net (tables)
Fair Value Measurements
Fair Value Measurements (reconciliation Of Changes In The Fair Value Of Liabilities) (details)
Fair Value Measurements (schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis) (details)
Fair Value Measurements (tables)
Income Taxes
Income Taxes (narrative) (details)
Income Taxes (schedule Of Deferred Tax Assets And Valuation Allowance) (details)
Income Taxes (tables)
Marketable Securities
Marketable Securities (narrative) (details)
Marketable Securities (schedule Of Cost And Fair Value Of Marketable Securities) (details)
Marketable Securities (tables)
Mediation Settlement
Mediation Settlement (details)
Net Loss Per Common Share
Net Loss Per Common Share (details)
Operations And Organization
Operations And Organization (details)
Other Liabilities
Other Liabilities (narrative) (details)
Other Liabilities (schedule Of Deferred Lease Incentive) (details)
Other Liabilities (tables)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (details)
Prepaid Expenses And Other Current Assets (tables)
Select Quarterly Data
Select Quarterly Data (details)
Select Quarterly Data (tables)
Stock-based Compensation
Stock-based Compensation (narrative) (details)
Stock-based Compensation (schedule Of Assumptions Made In Calculating The Fair Value Of Options) (details)
Stock-based Compensation (summary Of Employee And Non-employee Transactions) (details)
Stock-based Compensation (summary Of Stock Compensation Expense) (details)
Stock-based Compensation (summary Of Unvested Shares) (details)
Stock-based Compensation (tables)
Subsequent Events
Subsequent Events (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (narrative) (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (schedule Of Estimated Useful Lives) (details)
Summary Of Significant Accounting Policies (tables)
Warrants
Warrants (narrative) (details)
Warrants (schedule Of Assumptions Used In Calculating Fair Value Of Warrants) (details)
Warrants (schedule Of Fair Value Of Warrants Issued) (details)
Warrants (schedule Of Unrealized Gain/(loss) On Fair Value Of Warrants) (details)
Warrants (summary Of Changes In Warrants Outstanding During The Period) (details)
Warrants (summary Of Shares Indexed To The Warrants) (details)
Warrants (tables)
Ticker: RNN
CIK: 1228627
Form Type: 10-K Annual Report
Accession Number: 0001140361-17-009132
Submitted to the SEC: Fri Feb 24 2017 4:16:32 PM EST
Accepted by the SEC: Fri Feb 24 2017
Period: Saturday, December 31, 2016
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/rnn/0001140361-17-009132.htm